Lyfius Pharma has announced the inauguration of its state-of-the-art Pen-G manufacturing facility, at Kakinada, Andhra Pradesh.

With an annual production capacity of 15,000 metric tonnes (MT), the facility was virtually inaugurated by Prime Minister Narendra Modi in the presence of other dignitaries.

This facility represents a strategic investment of Rs 2,500 crore, under the Government of India’s PLI Scheme, and exemplifies how private sector participation can significantly contribute to national growth, drive innovation, and enhance healthcare security.

The PLI scheme for the pharmaceutical sector aims to strengthen domestic manufacturing capabilities in critical KSMs, DIs, and APIs.

Commenting on the occasion, M.V. Rama Krishna, Director, Lyfius Pharma, said “The launch of our Pen-G facility is a significant milestone in our efforts to enhance local production and reduce import dependency for critical pharmaceutical ingredients.

This investment underscores our commitment to support the government’s vision of ‘Atmanirbhar Bharat’, establishing India as a global pharmaceutical manufacturing hub.”

Lyfius Pharma is engaged in the manufacturing of Penicillin-G. Its state-of-art facility situated at Kakinada, Andhra Pradesh, approved under the PLI (Production Linked Incentive) scheme, is dedicated towards ensuring self-sufficiency in the production of Penicillin-G, catering to both the domestic and international markets.

This is one of the largest fermentation-based antibiotic intermediates plant in India with cutting edge technology including high-volume fermenters and automated starch & glucose plant.